Literature DB >> 20190799

Cross talk between stimulated NF-kappaB and the tumor suppressor p53.

G Schneider1, A Henrich, G Greiner, V Wolf, A Lovas, M Wieczorek, T Wagner, S Reichardt, A von Werder, R M Schmid, F Weih, T Heinzel, D Saur, O H Krämer.   

Abstract

Nuclear factor-kappaB (NF-kappaB) and p53 critically determine cancer development and progression. Defining the cross talk between these transcription factors can expand our knowledge on molecular mechanisms of tumorigenesis. Here, we show that induction of replicational stress activates NF-kappaB p65 and triggers its interaction with p53 in the nucleus. Experiments with knockout cells show that p65 and p53 are both required for enhanced NF-kappaB activity during S-phase checkpoint activation involving ataxia-telangiectasia mutated and checkpoint kinase-1. Accordingly, the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) also triggers formation of a transcriptionally active complex containing nuclear p65 and p53 on kappaB response elements. Gene expression analyses revealed that, independent of NF-kappaB activation in the cytosol, TNF-induced NF-kappaB-directed gene expression relies on p53. Hence, p53 is unexpectedly necessary for NF-kappaB-mediated gene expression induced by atypical and classical stimuli. Remarkably, data from gain- and loss-of function approaches argue that anti-apoptotic NF-kappaB p65 activity is constitutively evoked by a p53 hot-spot mutant frequently found in tumors. Our observations suggest explanations for the outstanding question why p53 mutations rather than p53 deletions arise in tumors of various origins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190799     DOI: 10.1038/onc.2010.46

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

1.  Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer.

Authors:  Gouri Sankar Sen; Suchismita Mohanty; Dewan Md Sakib Hossain; Sankar Bhattacharyya; Shuvomoy Banerjee; Juni Chakraborty; Shilpi Saha; Pallab Ray; Pushpak Bhattacharjee; Debaprasad Mandal; Arindam Bhattacharya; Samit Chattopadhyay; Tanya Das; Gaurisankar Sa
Journal:  J Biol Chem       Date:  2011-10-19       Impact factor: 5.157

2.  A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.

Authors:  Huayi Li; Wenxin Zhang; Kunming Zhao; Dong Zhao; Shanliang Zheng; Ying Hu
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

3.  Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS).

Authors:  Mickaël Ohanna; Sandy Giuliano; Caroline Bonet; Véronique Imbert; Véronique Hofman; Joséphine Zangari; Karine Bille; Caroline Robert; Brigitte Bressac-de Paillerets; Paul Hofman; Stéphane Rocchi; Jean-François Peyron; Jean-Philippe Lacour; Robert Ballotti; Corine Bertolotto
Journal:  Genes Dev       Date:  2011-06-06       Impact factor: 11.361

4.  p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-κB.

Authors:  Renée F Johnson; Ini-Isabée Witzel; Neil D Perkins
Journal:  Cancer Res       Date:  2011-07-08       Impact factor: 12.701

Review 5.  Combination Therapies Targeting HDAC and IKK in Solid Tumors.

Authors:  Ivana Vancurova; Mohammad M Uddin; Yue Zou; Ales Vancura
Journal:  Trends Pharmacol Sci       Date:  2017-12-09       Impact factor: 14.819

6.  Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.

Authors:  Laura Conradt; Klaus Godl; Christoph Schaab; Andreas Tebbe; Stefan Eser; Sandra Diersch; Christoph W Michalski; Jörg Kleeff; Angelika Schnieke; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

7.  HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

Authors:  Susanne Schüler; Petra Fritsche; Sandra Diersch; Alexander Arlt; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  Mol Cancer       Date:  2010-04-16       Impact factor: 27.401

8.  IkappaBbeta is an essential co-activator for LPS-induced IL-1beta transcription in vivo.

Authors:  Melanie Scheibel; Bettina Klein; Heidrun Merkle; Manon Schulz; Ralph Fritsch; Florian R Greten; Melek C Arkan; Günter Schneider; Roland M Schmid
Journal:  J Exp Med       Date:  2010-10-25       Impact factor: 14.307

9.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Authors:  Tomer Cooks; Ioannis S Pateras; Ohad Tarcic; Hilla Solomon; Aaron J Schetter; Sylvia Wilder; Guillermina Lozano; Eli Pikarsky; Tim Forshew; Nitzan Rosenfeld; Nitzan Rozenfeld; Noam Harpaz; Steven Itzkowitz; Curtis C Harris; Varda Rotter; Vassilis G Gorgoulis; Moshe Oren
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

Review 10.  p53 and the Carcinogenicity of Chronic Inflammation.

Authors:  Andrei V Gudkov; Elena A Komarova
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.